A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs LCL 161 (Primary) ; Paclitaxel
- Indications Breast cancer; Triple negative breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Novartis
- 20 Sep 2018 Results of a biomarker analysis published in the Journal of Clinical Oncology.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.